For research use only. Not for therapeutic Use.
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures[1][2].
KL1333 is a potent modulator of the cellular levels of NAD⁺, a central co-enzyme in the cell’s energy metabolism. Elevated NAD+ levels triggers the activation of SIRT1 and AMPK, and subsequently activates PGC-1α[1].
Catalog Number | I018055 |
CAS Number | 1800405-30-4 |
Synonyms | 2-propan-2-yl-3H-benzo[e]benzimidazole-4,5-dione |
Molecular Formula | C14H12N2O2 |
Purity | ≥95% |
InChI | InChI=1S/C14H12N2O2/c1-7(2)14-15-10-8-5-3-4-6-9(8)12(17)13(18)11(10)16-14/h3-7H,1-2H3,(H,15,16) |
InChIKey | AJFWITSBVLLDCC-UHFFFAOYSA-N |
SMILES | CC(C)C1=NC2=C(N1)C(=O)C(=O)C3=CC=CC=C32 |
Reference | [1]. Seo KS, et al. KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts. Front Neurol. 2018;9:552. Published 2018 Jul 5. [2]. Lee HS, et al. KL1333, a derivative of β-lapachone, protects against cisplatin-induced ototoxicity in mouse cochlear cultures. Biomed Pharmacother. 2020;126:110068. |